NEW HAVEN, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

Extended-release 7-day injectable buprenorphine was safe and tolerable for most patients who had minimal-to-mild opioid withdrawal, a nonrandomized trial found. Among 100 adult patients with ...

Patients with opioid use disorder who received yoga as an adjuvant therapy experienced improved autonomic regulation and ...

With historically high overdose death rates in U.S., multi-site NIH study reinforces importance of continued, uninterrupted access to addiction medication Results from a multi-site clinical trial ...

Opiate withdrawal is typically associated with flu-like symptoms that can be severe but improve over time. In rare cases, death is possible when withdrawal leads to extreme dehydration, a dangerous ...

The trial recruited adult patients with untreated moderate to severe opioid use disorder, opioid-positive and methadone-negative urine tests, and a Clinical Opiate Withdrawal Scale score greater than ...

Adding yoga to standard care for opioid use disorder (OUD) may speed up recovery from opioid withdrawal and improve nervous system regulation, results from a new randomized clinical trial suggested.

An early-stage randomized trial showed that yoga alongside standard buprenorphine therapy hastened opioid withdrawal recovery and improved autonomic regulation compared with buprenorphine alone.

Spark Biomedical is joined by the Battelle Memorial Institute and Hazelden Betty Ford Foundation to begin pioneering an AI-powered, wearable, closed-loop neurostimulation system to improve opioid ...